IMV Inc (IMV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

IMV Inc (IMV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH139059D
  • |
  • Pages: 56
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

IMV Inc (IMV) formerly known as Immunovaccine Inc, is a clinical-stage immuno-oncology company that develops cancer immunotherapies and infectious disease vaccines. The company develops its products based on DepoVax platform, a vaccine adjuvant and delivery platform technology. Its immuno oncology pipeline products are intended for the treatment of ovarian, diffuse large B cell lymphoma (DLBCL) tumors and human papillomavirus (HPV) cervical cancer. IMV's infectious disease product candidates are intended for the treatment of respiratory syncytial virus, malaria and others. The company partners with various universities, research institutes and other vaccine development companies to develop its product candidates for applications in cancer and infectious diseases. IMV is headquartered in Halifax, Nova Scotia, Canada.

IMV Inc (IMV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

IMV Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

IMV Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

IMV Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

PCI Biotech Enters into Agreement with IMV 11

Immunovaccine Enters into Agreement with Incyte 12

Immunovaccine Enters into Agreement with University of Edinburgh 13

Immunovaccine Extends Partnership with UConn Health 14

Immunovaccine Expands Agreement with Leidos 15

Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 16

ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 17

Equity Offering 18

IMV Plans to Raise up to USD150 Million in Public Offering of Securities 18

Immunovaccine Raises USD11.6 Million in Public Offering of Shares 19

Immunovaccine Raises USD7.4 Million in Public Offering of Shares 20

Immunovaccine Raises USD6 Million in Private Placement of Shares 21

Immunovaccine Raises USD6.2 Million in Private placement of Units 22

Immunovaccine Raises USD8.7 Million in Public Offering of Units 24

Immunovaccine Raise USD1.58 Million in Private Placement of Shares 26

Immunovaccine Withdraws Prospectus For Public Offering Of Shares For USD6.8 Million 27

Immunovaccine Withdraws Private Placement Of Shares For USD1 Million 28

Immunovaccine Completes Private Placement Of Shares For USD4 Million 29

Immunovaccine Completes Private Placement Of Units For USD1.6 Million 30

Immunovaccine Completes Private Placement Of Common Stock For USD2.8 Million 32

IMV Inc-Key Competitors 33

IMV Inc-Key Employees 34

IMV Inc-Locations And Subsidiaries 35

Head Office 35

Recent Developments 36

Financial Announcements 36

May 14, 2018: IMV Announces Q1 2018 Financial Results 36

Mar 20, 2018: Immunovaccine Announces Year-End 2017 Financial Results 38

Nov 09, 2017: Immunovaccine Announces Third Quarter 2017 Financial Results 40

Aug 08, 2017: Immunovaccine Announces Financial Results for Quarter Ended June 30, 2017 41

May 10, 2017: Immunovaccine Announces Financial Results for Quarter Ended March 31, 2017 43

Mar 30, 2017: Immunovaccine Announces 2016 Year-End Results 44

Corporate Communications 47

Jun 07, 2018: IMV Appoints Julia P. Gregory to Board of Directors 47

May 31, 2018: Nasdaq Approves Listing of IMV Common Shares 48

Jan 18, 2018: Immunovaccine Appoints Joseph Sullivan as Senior Vice President of Business Development 49

Feb 03, 2017: Immunovaccine Appoints Seasoned Financial Executive Pierre Labbe as CFO 50

Product News 51

Jan 31, 2018: Published Study Demonstrates the Association Between Immunovaccine's Proprietary Immune-targeted Delivery Technology and Enhanced Efficacy in Slowing Tumor Progression 51

Clinical Trials 52

Oct 05, 2017: Immunovaccine Researchers to Present Data at Two Upcoming Conferences that Demonstrate the Broad Applicability of the Companys DepoVax-based Programs 52

Apr 12, 2017: Immunovaccine Announces Positive Year-Long Immunogenicity Data from Phase 1 Clinical Trial for Respiratory Syncytial Virus Vaccine Candidate 53

Other Significant Developments 54

May 10, 2018: IMV-Change of ticker on OTCQX from IMMVF to IMMVD 54

Aug 08, 2017: Immunovaccine Issues Second Quarter 2017 Letter to Shareholders 55

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56

List of Figures

IMV Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

IMV Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

IMV Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

IMV Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

IMV Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

IMV Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

IMV Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

IMV Inc, Deals By Therapy Area, 2012 to YTD 2018 9

IMV Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

PCI Biotech Enters into Agreement with IMV 11

Immunovaccine Enters into Agreement with Incyte 12

Immunovaccine Enters into Agreement with University of Edinburgh 13

Immunovaccine Extends Partnership with UConn Health 14

Immunovaccine Expands Agreement with Leidos 15

Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 16

ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 17

IMV Plans to Raise up to USD150 Million in Public Offering of Securities 18

Immunovaccine Raises USD11.6 Million in Public Offering of Shares 19

Immunovaccine Raises USD7.4 Million in Public Offering of Shares 20

Immunovaccine Raises USD6 Million in Private Placement of Shares 21

Immunovaccine Raises USD6.2 Million in Private placement of Units 22

Immunovaccine Raises USD8.7 Million in Public Offering of Units 24

Immunovaccine Raise USD1.58 Million in Private Placement of Shares 26

Immunovaccine Withdraws Prospectus For Public Offering Of Shares For USD6.8 Million 27

Immunovaccine Withdraws Private Placement Of Shares For USD1 Million 28

Immunovaccine Completes Private Placement Of Shares For USD4 Million 29

Immunovaccine Completes Private Placement Of Units For USD1.6 Million 30

Immunovaccine Completes Private Placement Of Common Stock For USD2.8 Million 32

IMV Inc, Key Competitors 33

IMV Inc, Key Employees 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

IMV Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 17970
Site License
USD 500 INR 35940
Corporate User License
USD 750 INR 53910

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com